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Objectives This study sought to assess the consequences of switching prasugrel to clopidogrel on
platelet inhibition and clinical outcomes after an acute coronary syndrome (ACS).
Background Many ACS patients are switched from prasugrel to clopidogrel within the recom-
mended 1-year duration of treatment.
Methods Platelet reactivity was measured with the VerifyNow P2Y12 assay (Accumetrics, San Diego,
alifornia) in 300 ACS patients treated for 15 days with prasugrel 10 mg. Patients displaying low
n-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel
5 mg and tested again 15 days later. The rate of patients with high on-treatment platelet reactivity
HPR), P2Y12 reaction units (PRU) 208, and LPR (PRU 0) were evaluated before and after the
switch. Bleeding and ischemic events were also recorded.
Results On a regimen of prasugrel 10 mg, the rate of patients with LPR was 45.6% (n  137),
whereas 4.3% (n  13) had HPR. A group of 31 patients (10.3%) was switched to clopidogrel 75 mg,
of whom 29 had LPR (93.5%) on a regimen of prasugrel. On-treatment platelet reactivity (PRU) in-
creased from 14  4 on a regimen of prasugrel to 155 15 on a regimen of clopidogrel (p 
0.0001), resulting in a much lower rate of patients with LPR (9.7%). The rate of patients with HPR
increased from 0% with prasugrel to 29% (n  9) with clopidogrel. The rate of minor bleeding de-
creased after the switch from 32.2% to 9.7%; p  0.03.
Conclusions An LPR is frequent in patients treated with prasugrel 10 mg. Early switching from prasug-
rel 10 mg to clopidogrel 75 mg reduces the number of patients with LPR and minor bleeding events but
unmasks a group of nonresponders to clopidogrel with unknown consequences on clinical outcomes. (J Am
Coll Cardiol Intv 2013;6:158–65) © 2013 by the American College of Cardiology Foundation
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159Prasugrel has been the first P2Y12 antagonist available to
overcome clopidogrel poor response with a significant im-
provement in clinical outcome of acute coronary syn-
drome (ACS) patients (1). Prasugrel has become a
first-line therapy especially in ST-segment elevation
myocardial infarction patients (2) and in diabetic patients
(3) undergoing primary percutaneous coronary intervention
(PCI). American and European guidelines recommend dual
See page 166
antiplatelet therapy for 1 year after an acute ACS; mainte-
nance therapy with prasugrel relies on a daily dose of 10 mg
or a reduced dose of 5 mg in elderly patients (75 years)
and in low body weight (60 kg) patients (4,5). Despite the
evidence for a consistent and sustained clinical benefit with
prasugrel in the long term, many physicians switch their
patients to clopidogrel before the end of the recommended
1-year period of treatment. The main reason for a strategy
of switching seems to be safety concerns. However, the
pharmacodynamic and clinical impact of switching prasug-
rel to clopidogrel is unknown. The aim of our study was to
assess platelet reactivity and clinical outcomes in ACS
patients before and after a switch from prasugrel 10 mg to
clopidogrel 75 mg.
Methods
Study design. Acute coronary syndrome patients treated by
CI and prasugrel 10 mg at the Pitié-Salpêtrière hospital in
aris were prospectively monitored for platelet reactivity 15
ays after hospital discharge. After clinical examination and
latelet function monitoring, some patients were switched
o clopidogrel 75 mg maintenance dose. The decision was
eft to the discretion of the physician, and the reasons for the
witch were recorded. A second platelet reactivity measure-
ent was carried out 15 days later in patients who were
witched to clopidogrel. Platelet reactivity was evaluated
ith the VerifyNow P2Y12 assay (Accumetrics, San Diego,
alifornia), light transmission aggregometry (LTA), and
he vasodilator-stimulated phosphoprotein (VASP) platelet
eactivity index (PRI) according to methods and definitions
sed in previous studies (6,7). Clinical follow-up evaluated
leeding and ischemic events up to 30 days. Patient char-
cteristics were entered into a prospective web-based regis-
ry (ONASSIST [ONline ASSIstance for Stent Thrombo-
is] registry) regrouping clinical and biological data as well
s the identification of drug intake to evaluate potential
rug–drug interaction.
Study population. Patients entered in the prospective
ONASSIST registry for this study were treated by prasugrel
10 mg maintenance dose, the only dosage available in
France (8). Exclusion criteria for participation to the study flwere any contraindication to prasugrel, glycoprotein IIb/IIIa
antagonist administration within 7 days before inclusion,
and a low platelet count 100,000/ml. The Pitié-
Salpêtrière University Hospital Ethics Committee approved
the protocol, and the study was conducted in accordance
with the Declaration of Helsinki.
Platelet function tests. VERIFYNOW P2Y12 ASSAY. For the
VerifyNow P2Y12 assay (Accumetrics, San Diego, California),
samples were run according to the package insert. Results were
expressed in P2Y12 reaction units (PRU) in response to
so-Thrombin Receptor Activating Peptide and to adenosine
iphosphate (ADP)-prostaglandin E1 (PGE1) and in percentage
of inhibition corresponding to the
ratio of the results of the ADP-
PGE1 and iso-Thrombin Receptor
Activating Peptide channels.
LTA. Blood was collected into
ecton-Dickinson (Franklin Lakes,
ew Jersey) 3.2% citrate vacu-
tte tubes. Platelet-rich plasma
as obtained by centrifugation
f citrated whole blood at 1,000
for 10 min at 20°C. Platelet-
oor plasma was obtained by
urther centrifugation at 4,500 g
or 15 min. In vitro platelet ag-
regation in platelet-rich plasma
as measured at 37°C by LTA
model 490-4D; Chrono-Log
orp., Kordia, the Netherlands)
nd was induced by the addition
f ADP (Sigma-Aldrich, Saint-
uentin Fallavier, France) at fi-
al concentration of 20 mol/l.
ll measurements were performed
n duplicate and results were ex-
ressed in maximal platelet aggre-
ation (MPA) and residual platelet
ggregation (RPA) measured at 6
in. Pre-specified criteria used to
efine non-evaluable samples were
ack of sufficient signal, hemolysis,
nd platelet count 100,000/ml and an unstable baseline.
VASP-PRI. The phosphorylation of the VASP was mea-
sured with a Beckman Coulter FC500 cytometer (Beck-
man Coulter, Villepinte, France) or with enzyme-linked
immunoadsorbent assay VASP-P technique (Thermo
Scientific Multiskan Ascent, BioCytex, Stago, Paris,
France) according to manufacturer instructions and pre-
vious studies. Blood samples were incubated in vitro with
ADP and PGE1 before fixation. The VASP PRI mea-
ured by flow cytometer was calculated from the median
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
BARC  Bleeding Academy
Research Consortium
HPR  high on-treatment
platelet reactivity
LPR  low on-treatment
platelet reactivity
LTA  light transmission
aggregometry
MFI  median fluorescence
intensity
MPA  maximal platelet
aggregation
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
PRI  platelet reactivity
index
PRU  P2Y12 reaction units
RPA  residual platelet
aggregation
VASP  vasodilator-
stimulated phosphoproteinuorescence intensity (MFI) of each condition according
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160to the formula: VASP PRI  ([MFI (PGE1)  MFI
PGE1  ADP)]/MFI [PGE1])  100.
Study endpoints. The main endpoint was the variation in
the rate of both high on-treatment platelet reactivity (HPR)
and low on-treatment platelet reactivity (LPR) before and
after the switch from prasugrel 10 mg maintenance dose to
clopidogrel 75 mg maintenance dose, with the PRU from
the VerifyNow P2Y12 platform assay with the predefined
hresholds of PRU 208 for HPR (9) and PRU 30 for
PR (10), respectively.
Other endpoints were the variations in the rate of HPR
nd LPR before and after the switch, with VASP index and
TA with cutoff values of PRI 50% and percentage of
esidual platelet inhibition 46.2% or maximal platelet
nhibition 59% for HPR with VASP and LTA, respec-
ively (11,12). Due to the lack of a consensus definition of
PR with VASP and LTA, the thresholds were determined
etrospectively as the 25th percentile of values of our overall
atabase and calculated as a PRI 10%, RPA 1%, and
PA 20.5%, respectively.
The therapeutic window was defined as: 1) PRU
etween 30 and 208; 2) PRI between 10% and 50%; 3)
PA between 1% and 46.2%; or 4) MPA between 20.5%
nd 59%.
Table 1. Baseline Characteristics
Characteristic
All Patients
(n  300)
Age, yrs 60.79 12.65
Women, % 17.33 37.92
Weight, kg 77.88 13.73
BMI kg/m2 26.49 4.17
Low-weight 60 kg 11.33 31.75
BMI 30 kg/m2 16.67 37.33
Diabetes, % 27.67 44.81
Dyslipidemia, % 45.33 49.86
Smoker, % 54.33 49.90
High blood pressure, mm Hg 46.00 49.92
Familial History of CAD, % 18.33 38.76
1-vessel disease, % 50.50 50.08
2-vessel disease, % 30.77 46.23
3-vessel disease, % 18.73 39.08
CrCl, ml/min 95.46 37.88
EF, % 51.84 9.48
ASA, mg 76.98 13.11
Beta blockers, % 89.33 30.92
ACE inhibitors, % 83.67 37.03
Calcium antagonist, % 11.67 32.16
Statins, % 94.00 23.79
Proton pump inhibitors, % 75.67 42.98
Values are Mean SD, *p 0.05.
ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acidclearance; EF ejection fraction.Another endpoint was the variation in the rate of minor
nd major bleeding events according to the Bleeding Acad-
my Research Consortium (BARC) classification (13) and
schemic events, stent thrombosis, and myocardial infarc-
ion up to 30 days.
Statistical analysis. On the basis of previous platelet func-
tion studies (6), at least 30 switched patients were needed
to yield 90% power with an alpha-risk error of 0.05,
assuming a 40% SD to demonstrate that switching from
prasugrel to clopidogrel led to a 90% higher level of
platelet reactivity as measured by the VerifyNow P2Y12.
ormal distribution of the variables was evaluated for
ontinuous variables with the Kolmogorov-Smirnov test.
ontinuous variables after a normal distribution are
resented as mean  SD and were compared with
tudent unpaired t test or paired t test when appropriate.
ategorical variables are presented as counts and percent-
ges and were compared by means of the chi-square test
r Fisher exact test. Results are reported as mean  SD
or the detailed analyses. All p values are 2-sided, and a
alue of p  0.05 was considered significant. All analyses
ere performed with PRISM (version 5; Graph Pad, San
iego, California). All the authors had full access to and
ake full responsibility for the integrity of the data.
No Switch
(n  269)
Switch
(n  31) p Value
60.28 12.64 65.25 11.99 0.04*
17.01 37.72 19.35 40.16 0.75
78.47 13.74 72.81 12.69 0.03*
26.62 4.25 25.29 3.22 0.09
10.04 30.11 22.58 42.50 0.04*
17.84 38.36 6.45 24.97 0.11
26.77 44.36 35.48 48.64 0.30
44.61 49.80 51.61 50.80 0.46
55.02 49.84 48.39 50.80 0.48
45.72 49.91 48.39 50.80 0.78
18.59 38.97 16.13 37.39 0.74
52.24 50.04 35.48 48.64 0.07
18.66 45.51 19.35 50.59 0.92
29.10 39.03 45.16 40.16 0.07
96.41 38.76 87.25 28.38 0.20
51.48 9.56 54.80 8.37 0.07
77.30 13.73 77.42 13.47 0.96
90.33 29.60 80.65 40.16 0.10
82.16 38.36 96.77 17.96 0.04*
11.90 32.43 9.67 30.05 0.72
94.05 23.70 93.55 24.97 0.91
75.09 43.33 80.65 40.16 0.50
body mass index; CAD  coronary artery disease; CrCl  creatinine; BMI 
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161Results
Study population. Of 345 ACS consecutive patients who
entered the prospective ONASSIST registry being exposed
to a daily 10-mg maintenance dose of prasugrel, 300
patients agreed to participate in the study and had a platelet
function-testing visit 15 days after hospital discharge. Our
study population was a high-risk population, with one-third
of ST-segment elevation myocardial infarction patients who
underwent primary PCI and one-third of diabetic patients
who presented with non–ST-segment elevation myocardial
infarction and had PCI performed. Baseline characteristics
are presented in Table 1.
Platelet response to prasugrel 10 mg. The rate of patients
ith HPR and LPR at the first visit was 4.3% (n  13 of
300) and 45.6% (n  137 of 300), respectively, according
to the predefined PRU cutoff levels of 208 and 30
(Fig. 1). With the other platelet function tests, the rates
of HPR were 2.0% with RPA, 2.6% with MPA, and 6.7%
with VASP testing. The rates of LPR with VASP, RPA,
and MPA were 24.3%, 38.6%, and 24.7%, respectively.
A total of 31 prasugrel-treated patients (10.3%) were
switched to a clopidogrel maintenance dose of 75 mg
after the first monitoring-visit. Baseline characteristics of
patients who were switched to clopidogrel versus those
who were maintained on a regimen of prasugrel 10 mg
Figure 1. On-Treatment Platelet Reactivity With Prasugrel 10 mg at 15 Da
The rates of high on-treatment platelet reactivity were 4.3%, 6.7%, 2%, and 2.6
phosphoprotein measurement, residual platelet aggregation (RPA), and maxim
reactivity were 45.6%, 24.3%, 38.7%, and 24.7% with Verify Now, vasodilator-st
phate; PRI  platelet reactivity index; PRU  P2Y12 reaction units.are presented in Table 1. Switched patients were signif-
icantly older and displayed a lower body weight and a
higher rate of LPR. The LPR was observed in 93.5%
versus 39.8% in switched versus nonswitched patients
(p  0.0001). One patient without LPR was switched to
clopidogrel because of a suspected allergic reaction (skin
rash), and 1 was switched because of a bleeding BARC 2
(hematemesis).
Pharmacodynamic impact of the switch. The switch from
prasugrel to clopidogrel led to a 10-fold increase in PRU
level (from 14.23  22 before switching to 155.0  87 after
switching, p  0.000 1). One-third of the patients who
switched to clopidogrel displayed HPR, whereas there was
none on a prasugrel regimen. The rate of LPR was reduced
by 10-fold and finally present in 10% of patients main-
tained on a regimen of clopidogrel (Fig. 2). The other tests
showed consistent results as presented in Table 2. The rates
of HPR on clopidogrel 75 mg were 19%, 22.6%, and 38%
with RPA, MPA, and VASP-PRI, respectively. In contrast,
the rates of LPR were 0%, 6.5%, and 10% with RPA, MPA,
and VASP-PRI, respectively (p  0.000 1) (Fig. 3).
In the switched group, the clinical characteristics associ-
ated with a poor response to clopidogrel were age (62.63 
12.03 vs. 71.63  9.69, p  0.056) and creatinine clearance
(95.40  27.39 vs. 67.33  20.57, p  0.01).
h VerifyNow (Accumetrics, San Diego, California), vasodilator-stimulated
telet aggregation (MPA), respectively. The rates of low on-treatment platelet
ted phosphoprotein, RPA, and MPA, respectively. ADP  adenosine diphos-ys
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162Short-term outcomes. Clinical follow-up was obtained in all
patients at 1-month follow-up. There was no Thrombolysis
In Myocardial Infarction major bleeding with prasugrel.
Bleeding Academy Research Consortium 1 and BARC 2
bleedings were reported in one-fifth of patients exposed to
prasugrel 10 mg maintenance dose (17.1% and 3.2%,
respectively). In the overall population there was no isch-
emic event after 1-month follow-up. Of interest, patients
who were switched to clopidogrel tended to have a higher
rate of bleeding under prasugrel 10 mg maintenance dose
than those who were not switched (32.3% vs. 18.1%,
respectively; p 0.078). Patients switched to clopidogrel 75
mg and reevaluated after the shift have a decreased rate of
bleeding events during the clopidogrel period when com-
pared with the first period on a regimen of prasugrel 10 mg.
Indeed, bleeding events (BARC 1 and 2) decreased from
32.2% under prasugrel to 9.7% during the clopidogrel
period (p  0.03) (Fig. 4).
Discussion
If the pharmacological impact of switching from clopidogrel
to prasugrel has been evaluated in several studies (7,14), this
investigation is, to our knowledge, the first “real-life”
evaluation of a pharmacodynamically driven switch strategy
Figure 2. Main Endpoint: Evolution of PRU After Switch From Prasugrel
10 mg to Clopidogrel 75 mg
The lower red line indicates the threshold for low on-treatment plate-
let reactivity (P2Y12 reaction units [PRU] 30) and the upper red line
indicates the threshold for high on-treatment platelet reactivity (PRU
208).from prasugrel to clopidogrel. The first finding is that highon-prasugrel platelet reactivity is a rare phenomenon found
in 1 of 20 patients, whereas one-half of patients display
low on-prasugrel platelet reactivity. The second finding is
that prasugrel-treated patients who are switched to clopi-
dogrel on the basis of LPR also display clinical character-
istics known to be associated with an increased risk of
bleeding (e.g., age 75 years old, low-weight). Third, the
witch strategy led to an important reduction of platelet
nhibition unmasking high platelet reactivity in one-third of
atients taking clopidogrel, some of these patients exhibit-
ng real pharmacodynamic resistance to clopidogrel. The
witch strategy is also associated with less frequent minor
leeds.
Switching from a potent platelet inhibitor with a higher
leeding hazard to a weaker agent of the same class of
hienopyridines might be justified, especially in patients at
igher risk of bleeding. According to TRITON (Trial to
ssess Improvement in Therapeutic Outcomes by Optimiz-
ng Platelet Inhibition With Prasugrel) post-hoc analyses,
lderly patients (over 75 years old) and low body weight
atients (under 60 kg) have a higher risk of bleeding on a
egimen of prasugrel 10 mg maintenance dose, altering the
et clinical benefit of prasugrel in these patients (15).
herefore, we report here in a real-life ACS population that
PR identification by monitoring as well as factors such as
dvanced age, low body weight, or presence of nuisance
leeding are associated with the decision of switching from
rasugrel to clopidogrel. Low on-treatment platelet reactiv-
ty is also found in the nonswitched population but to a
uch lower extent; the good tolerance of the drug and the
bsence of obvious risk factor for bleeding might explain the
ecision of keeping these patients maintained on a regimen
f prasugrel, especially with monitoring values in the target
indow of efficacy without excess platelet inhibition. We
elieve that the combination of an unfavorable safety profile
Table 2. Results of Different Platelet Function Tests Before and
After Switch
Prasugrel
10 mg
Clopidogrel
75 mg
p
Values
VerifyNow (P2Y12) n  31 (100%) n  31 (100%)
Base (iso-TRAP) (PRU) 283.7 53.07 285.5 42.37 0.88
Patient (ADP-PGE1) (PRU) 14.23 21.98 155.0 87.24 0.0001
% inhibition 94.67 8.36 47.17 27.44 0.0001
LTA n  31 (100%) n  31 (100%)
MPA ADP 20 mol/l 21.01 10.47 43.84 15.19 0.0001
RPA ADP 20 mol/l 2.22 5.80 26.45 19.59 0.0001
VASP n  28 (90%) n  22 (71%)
PRI 12.55 11.90 43.63 21.82 0.0001
Values are mean SD.
ADP-PGE1  adenosine diphosphate prostaglandin E1; iso-TRAP  iso-Thrombin Receptor
ActivatingPeptide; LTA light transmission aggregometry;MPImaximal platelet aggregation;
PRI platelet reactivity index; PRU P2Y12 reaction units; RPA residual platelet aggregation;VASP vasodilator-stimulated phosphoprotein.
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163of the patient and LPR measured by monitoring convinced
the physicians to switch from prasugrel to clopidogrel. The
switch could be driven by cost issues, low education level,
and compliance reasons—in addition to medical reasons
related to safety concerns—and expose the patients to
complications. In the present study, patients were all fully
supported by our universal health care system, and drug cost
was not considered in the decision to switch treatment.
High on-treatment platelet reactivity is well-defined for
clopidogrel (11) and has been clearly identified as a risk
marker for ischemic events (16,17). High on-treatment
platelet reactivity can also exist with prasugrel in ACS
patients after a loading dose of 60 mg (18) and to a lower
extent (6% of treated patients) on the maintenance dose of
10 mg (19). In contrast, only a few studies have investigated
low on-clopidogrel platelet reactivity, because it is infre-
quent and less well-defined (20). The same problem of
definition applies to the new P21Y12 inhibitors prasugrel
nd ticagrelor. There is a lack of data and no consensus
n the definition of LPR with VASP and LTA, because
t has rarely been an issue with clopidogrel. However, low
n-clopidogrel platelet reactivity is associated with a
igher risk of bleeding (21,22). The definition of low
n-prasugrel platelet reactivity in our study is also arbi-
rary. With our definitions, it is present in more than
ne-third of the treated population, a finding coherent
Figure 3. Pharmalogical Response Before and After the Switch
Rates (%) of patients with or without high on-treatment platelet reactivity (HP
Low on-treatment platelet reactivity (LPR) (hyper response) deﬁned as PRU 3
(red bars) and after (blue bars) the switch. All results are signiﬁcantly differen
tions as in Figure 1.ith previous reports (7).The underlying concept that is presented here is the
ailored antiplatelet therapy approach. Pharmacological
tudies support the existence of a “sweet spot” for P2Y12
receptor inhibition that might decrease the risk of both
bleeding and thrombotic events (23,24). As expected, selec-
tive switch from prasugrel to clopidogrel increased the rate
of ACS patients in the “therapeutic target window” of
platelet inhibition, defined in our study between 30 and 208
PRU. This might be because the patients selected are good
responders to thienopyridines in general. In our work, most
of the switched patients had LPR, and the switching
strategy rarely exposed patients to the risk of clopidogrel
resistance and potentially to a higher ischemic risk. If the
switch were more systematic without platelet function
monitoring, the risk of resistance to clopidogrel would be
higher and possibly more detrimental clinically. We fully
acknowledge that, despite the rationale for individualized
antiplatelet therapy, the clinical benefit of such a tailored
approach based on platelet function testing has not yet been
proven. Previous studies on tailored therapy (25,26) were
either neutral or stopped, due to low event rates or slow
recruitment. However, there is more evidence to use an
approach with pharmacodynamic information to improve
and understand a particular case, such as stent thrombosis
(27). Our finding emphasizes the need for more clinical
studies on tailored antiplatelet therapy, especially with the
or response), deﬁned as PRU 208, PRI 50%, RPA 46.2%, or MPA 59%.
10%, RPA 1%, or MPA 20.5% with the 3 platelet function tests before
p  0.001. VASP  vasodilator-stimulated phosphoprotein; other abbrevia-R) (po
0, PRI
t withnewest agents, such as prasugrel and ticagrelor. The results
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164of the ARCTIC (Double Randomization of a Monitoring
Adjusted Antiplatelet Treatment Versus a Common Anti-
platelet Treatment for DES Implantation, and Interruption
Versus Continuation of Double Antiplatelet Therapy) trial
(28) are expected to add important information on a
personalized approach of antiplatelet therapy. Reaching the
sweet spot of platelet inhibition to reduce both the ischemic
and bleeding risks still represents a challenge in the treat-
ment of ACS.
Study limitations. This study has limitations and biases
nherent to registries that evaluate a “real-life” population. It
as to be noted that the decision of switching the patients
rom 1 drug to the other was left to the discretion of the
hysician, who was aware of the results of the pharmaco-
ynamic tests. The current work is a pilot study with a
imited sample size, and therefore our results should be
nterpreted as being only exploratory. The limited number
f switched patients and the short-term follow-up might
imit our conclusions, but we might also underestimate the
alue of testing with such a short-term study.
onclusions
Switching from prasugrel to clopidogrel results in a signif-
icant increase of platelet reactivity and less minor bleeding,
but it also unmasks a group of poor responders to clopi-
dogrel with potential consequences on ischemic events.
Figure 4. Bleeding Events
Bleeding Events before and after the switch from prasugrel to clopidogrel.
BARC  Bleeding Academy Research Consortium.Monitoring platelet response to treatment in ACS patientsmight help optimize the net clinical benefit, but it remains
to be proven in large clinical trials.
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